Neurofarmacología y terapéutica experimental

Dr. Bruno Antonio Marichal Cancino

Trayectoria Académica


  • Jefe del Departamento de Fisiología y Farmacología (2018-2020).

  • Profesor investigador titular B, UAA (2017-actual).

  • Investigador Posdoctoral, UNAM (2014-2016).

  • Profesor Asociado, UAM-X (2014).

  • Doctorado en Ciencias, CINVESTAV, I.P.N. (2013).

  • Maestría en Ciencias, CINVESTAV, I.P.N. (2009).

  • Biólogo, UAM-X (2007).

Premios y distinciones

  • Investigador Nacional Nivel 1.

  • Miembro AMEFAR.

  • Miembro de "Society for Neuroscience" .

  • Programa Captación y Retención de Investigadores de Alto Nivel UAA.


Contacto

Email: bruno.marichal@edu.uaa.mx

Teléfono: (01)-(449) 910 7400 Ext. 51260

En el laboratorio, nos interesa comprender la Farmacología del sistema endocannabinoide.

Estamos interesados principalmente en los procesos de aprendizaje y memoria, control motor, regulación de la ingestión de alimentos y la adicción a sustancias. Estamos convencidos de que la comprensión del sistema endocannabinoide nos permitirá generar nuevas dianas terapéuticas para múltiples patologías humanas (e.g., trastorno obsesivo compulsivo, obesidad, adicciones, etc.).

Proyectos financiados

  • PRODEP UAA-PTC-200 - "Búsqueda de una profilaxis farmacológica para la obesidad: los receptores putativos a cannabinoides.."

  • UAA Convocatoria de impacto social.

  • CONACYT Proyecto postdoctoral 2019.

Miembros del laboratorio



Investigador postdoctoral

Dra. Priscila Vázquez León

SNI nivel 1




Miniproyectos

  • Jessica Gabriela Romo Padilla (2019).

  • Mario Alberto López Vázquez (2019).

  • Miguel Ángel Oropeza García (2019).

  • Perla Carolina Rodríguez Rojas (2020).


Estudiantes

Pregrado

  • Sharon Sarahí Vargas Castillo (QFB). Graduada

  • Isaura Edith Delgado Rodríguez (QFB) Graduada

  • Perla Carolina Rodríguez Rojas (Biología). Graduada

  • Arlene Stephanie Carrillo Castorena (Biotecnología). En proceso


Posgrado

  • Sergio Guzmán (Maestría). Graduado

  • Emmanuel Bernal Jasso (Maestría). En proceso

  • Alejandro Barba (Doctorado). En proceso

Verano de la ciencia

  • Dominic González Durán (2019)

  • Cristina Jenissia Aguayo Llamas (2019)

Lista de Publicaciones

  • (2020) NPY-Y1 receptors in dorsal periaqueductal gray modulate anxiety, alcohol intake, and relapse in Wistar rats. Pharmacol Biochem Behav. doi: 10.1016/j.pbb.2020.173071.

  • (2020) The locus of action of CGRPergic monoclonal antibodies against migraine: peripheral over central mechanisms. CNS Neurol Disord Drug Targets. doi: 10.2174/1871527319666200618144637.

  • (2020) Advances in Neurobiology and Pharmacology of GPR12. Front Pharmacol. doi: 10.3389/fphar.2020.00628.

  • (2020) Monoaminergic Receptors as Modulators of the Perivascular Sympathetic and Sensory CGRPergic Outflows. Curr Neuropharmacol. doi: 10.2174/1570159X18666200503223240.

  • (2020) Potential Mechanisms Involved in Palmitoylethanolamide-Induced Vasodepressor Effects in Rats. J Vasc Res. 3:1-12. doi: 10.1159/000506158

  • (2019) Potential metabolic and behavioural roles of the putative endocannabinoid receptors GPR18, GPR55 and GPR119 in feeding. Curr Neuropharmacol. 17(10):947-960. doi: 10.2174/1570159X17666190118143014

  • (2019) Antimicrobial and antibiofilm activity of biopolymer-Ni, Zn nanoparticle biocomposites synthesized using R. mucilaginosa UANL-001L exopolysaccharide as a capping agent. Int J Nanomedicine 14:2557-2571.

  • (2019) Functional Characterization of the Prejunctional Receptors Mediating the Inhibition by Ergotamine of the Rat Perivascular Sensory Peptidergic Drive. ACS Chem Neurosci.

  • (2019) Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. Front Pharmacol 9:1496.

  • (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol 14(1):25-41.

  • (2018) beta-Adrenoceptor Blockade for Infantile Hemangioma Therapy: Do beta3-Adrenoceptors Play a Role? J Vasc Res 55(3):159-168.

  • (2018) Dihydroergotamine inhibits the vasodepressor sensory CGRPergic outflow by prejunctional activation of alpha2-adrenoceptors and 5-HT1 receptors. J Headache Pain 19(1):40.

  • (2018) Possible role of hippocampal GPR55 in spatial learning and memory in rats. Acta Neurobiol Exp (Wars) 78(1):41-50.

  • (2017) Olcegepant blocks neurogenic and non-neurogenic CGRPergic vasodepressor responses and facilitates noradrenergic vasopressor responses in pithed rats. Br J Pharmacol 174(13):2001-2014.

  • (2017) Advances in the Physiology of GPR55 in the Central Nervous System. Curr Neuropharmacol 15(5):771-778.

  • (2016) Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases. Biomed Res Int 2016:2056786.

  • (2016) mGluR1/5 activation in the lateral hypothalamus increases food intake via the endocannabinoid system. Neurosci Lett 631:104-8.

  • (2016) Cardiovascular Alterations during the Interictal Period in Awake and Pithed Amygdala-Kindled Rats. Basic Clin Pharmacol Toxicol 119(2):165-72.

  • (2016) Further evidence for the role of histamine H3, but not H1, H2 or H4, receptors in immepip-induced inhibition of the rat cardioaccelerator sympathetic outflow. Eur J Pharmacol 773:85-92.

  • (2016) Blockade of GPR55 in the dorsolateral striatum impairs performance of rats in a T-maze paradigm. Behav Pharmacol 27(4):393-6.

  • (2015) Pharmacological evidence that histamine H3 receptors inhibit the vasodepressor responses by selective stimulation of the rat perivascular sensory CGRPergic outflow. Eur J Pharmacol 754:25-31.

  • (2015) Specific role of alpha2A - and alpha2B -, but not alpha2C -, adrenoceptor subtypes in the inhibition of the vasopressor sympathetic out-flow in diabetic pithed rats. Basic Clin Pharmacol Toxicol 117(1):31-8.

  • (2014) Role of pre-junctional CB1, but not CB2 , TRPV1 or GPR55 receptors in anandamide-induced inhibition of the vasodepressor sensory CGRPergic outflow in pithed rats. Basic Clin Pharmacol Toxicol 114(3):240-7.

  • (2014) The role of pre-junctional D2 -like receptors mediating quinpirole-induced inhibition of the vasodepressor sensory CGRPergic out-flow in pithed rats. Basic Clin Pharmacol Toxicol 114(2):174-80.

  • (2013) Analysis of anandamide- and lysophosphatidylinositol-induced inhibition of the vasopressor responses produced by sympathetic stimulation or noradrenaline in pithed rats. Eur J Pharmacol 721(1-3):168-77.

  • (2013) Predominant role of the dopamine D3 receptor subtype for mediating the quinpirole-induced inhibition of the vasopressor sympathetic outflow in pithed rats. Naunyn Schmiedebergs Arch Pharmacol 386(5):393-403.

  • (2013) The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats. Br J Pharmacol 170(5):1102-11.

  • (2012) Pharmacological evidence that spinal alpha(2C)- and, to a lesser extent, alpha(2A)-adrenoceptors inhibit capsaicin-induced vasodilatation in the canine external carotid circulation. Eur J Pharmacol 683(1-3):204-10.

  • (2012) Intrathecal dihydroergotamine inhibits capsaicin-induced vasodilatation in the canine external carotid circulation via GR127935- and rauwolscine-sensitive receptors. Eur J Pharmacol 692(1-3):69-77.

  • (2011) The dopamine receptors mediating inhibition of the sympathetic vasopressor outflow in pithed rats: pharmacological correlation with the D(2) -like type. Basic Clin Pharmacol Toxicol 109(6):506-12.

colaboradores cercanos


  • Dr. Carlos Miguel Villalón Herrera (SNI 3) Cinvestav-Sur.

  • Dr. Abimael González Hernández (SNI 2) INB-UNAM.

  • Dr. Paulino Barragán Iglesias (SNI 2) UAA.

  • Dra. Paula Morales Instituto de Química Médica (CSIC), España.

  • Dra. Raquel Guerrero Alba (SNI 1) UAA.

  • Dr. José Rubén Morones Ramírez (SNI 2) UANL.





Fecha de actualización: Agosto 2020